Response, resistance and treatment-free remission in CML
LINKS TO ABSTRACTS:
Presentation ID p410-1
Presenter: Mayra Gonzalez, El Paso, United States
The study authors conclude that all together, their data suggest that MYC-mediated G0S2 downregulation contributes to TKI resistance and blastic transformation of CML. Restoring G0S2 expression could have clinical utility by reestablishing TKI sensitivity in TKI-resistant patients and altering mitochondrial metabolism.
Presentation ID p410-2
Presenter: Ilaria Stefania Pagani, Adelaide, Australia
The study authors conclude that a greater number of mtDNA mutations was associated with a better molecular response in imatinib-treated patients. In a small number of patients, they found that mtDNA mutations with a higher VAF were associated with impaired OXPHOS in CD34+ cells at diagnosis. The study authors hypothesize that reduced OXPHOS may sensitize the leukemic cells to imatinib. Functional studies are ongoing.
Presentation ID p410-3
Presenter: Susanne Saussele, Germany
The study authors confirm with their final analysis the Molecular recurrence-free survival and MRecTFS rate at 6 months from the interim analysis. However, late relapses (15% between 6 and 36 months) occurred. Nevertheless, with 46%, almost half of the patients stayed at least in MRecTFS.
Presentation ID p410-4
Presenter: Jorge Cortes, Augusta, United States
The study authors conclude that the OPTIC primary analysis demonstrates the optimal benefit: risk profile for ponatinib was achieved with a response-based dosing regimen starting with 45 mg/d, followed by dose reduction to 15 mg/d upon achieving ≤1% BCR-ABL1IS; 30 mg →15 mg and 15 mg cohorts may provide benefit, especially in patients without T315I mutation (see Table). The observed ≤1% BCR-ABL1IS responses are supported by robust survival outcomes in patients with CP-CML resistant to second-generation BCR-ABL1 TKI therapy, both with and without BCR-ABL1 mutations.
Presentation ID p410-5
Presenter: Massimo Breccia, Italy
The study authors conclude that their study reports the 1-year of data on the Covid-19 infection in a specific hematological malignancy in the European country first hit by the pandemic.